| Literature DB >> 35011050 |
Dana Hasan Alkhatib1, Abdul Jaleel2, Maryam Naveed Muhammad Tariq1, Jack Feehan3, Vasso Apostolopoulos3,4, Leila Cheikh Ismail5,6, Lily Stojanovska1,3, Ayesha S Al Dhaheri1.
Abstract
Metabolic syndrome (MetS) is a combination of physiologically dysregulated parameters that can include elevated fasting blood glucose, high blood pressure, central obesity, increased triglyceride levels, insulin resistance, diabetes, elevated low density lipoprotein levels, and reduced high density lipoprotein levels in the blood. Effective clinical management of MetS is critical as it is strongly associated with long lasting and fatal complications in patients. Alongside standard care of lifestyle changes and medication, dietary supplements derived from herbal resources could be an alternative therapeutic strategy that is safe, efficient, culturally acceptable, and has few side effects. Of the dietary supplements, spicy foods have always been considered a great source of functional bioactive compounds. Herbal therapy is broadly used in many countries as a treatment or as a preventive measure in the management of MetS risk factors, including blood glucose, blood pressure, and blood lipid levels. Herein, an attempt is made to evaluate the recent studies in the management of MetS with herbal alternatives, and to explore the possibility of their use as therapeutic treatments or supplements.Entities:
Keywords: bioactive compounds; diet therapy; herbal therapy; metabolic syndrome; natural products
Mesh:
Substances:
Year: 2021 PMID: 35011050 PMCID: PMC8747161 DOI: 10.3390/nu14010175
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Studies and clinical trials on the effects of herbs and spices on metabolic syndrome risk factors.
| Herbs | Target/Groups | Dose/Duration | Main Outcome | Study |
|---|---|---|---|---|
| Slimax: extract of several plants: Hordeum vulgare, Polygonatum multiflorum, Dimocarpus longan, Ligusticum sinense, Lilium brownie, and Zingiber officinale | Healthy participants | 6 weeks | Significant decrease in body weight and body mass index (BMI). | [ |
| Significant reduction in waist and hip circumference. | ||||
| Herbal supplement: (Ma Huang & Guarana) | Overweight participants | 72 mg of ephedra and 240 mg of caffeine for 8 weeks. | Significant decrease in body weight and total body fat. | [ |
| -Control group ( | Significant reduction in hip and waist circumference. | |||
| -Intervention group ( | ||||
| A compound of | Obese non-diabetic women, | 450 mg of | Decrease in total body weight and fat weight. | [ |
| -Control group: Diet + placebo, | Reduction in plasma TGs. | |||
| -Intervention group: | ||||
| Diet + compound, | ||||
| White bean extract | Obese adults | 3000 mg per day of each for 8 weeks. | Weight reduction in the intervention group. | [ |
| -Control group: placebo, | Decrease in plasma TGs. | |||
| -Intervention group: white bean extract, | ||||
| Turmeric ( | Prediabetic adults | 750 mg per day of each for 9 months. | 16.4% of subjects in the placebo group were diagnosed with type 2 diabetes mellitus. | [ |
| -Control group: placebo, | None of the participants from the | |||
| -Intervention group: | ||||
| Korean red ginseng (KRG) ( | Overweight participants | 6 g per day of each for 12 weeks. | No change in HbA1c in both groups. | [ |
| Intervention group maintained good glycemic control and improved plasma glucose and plasma insulin regulation. | ||||
| -Control group: placebo, | ||||
| -Intervention group: KRG, | ||||
| Bitter lemon ( | Newly diagnosed with diabetes adults, | 3 g per day of each for 12 weeks. | There was no significant effect on mean FBG, total cholesterol, and weight in both groups. | [ |
| -Control group: placebo, | ||||
| -Intervention group: | ||||
| Cinnamon ( | Participants diagnosed diabetes mellitus type 2 | 3 g per day of each for 16 weeks. | The cinnamon extract has a moderate effect in reducing fasting plasma glucose concentrations in diabetic patients. | [ |
| -Control group: placebo, | ||||
| -Intervention group: cinnamon powder, | ||||
| A combination of | Overweight and obese participants | Intervention group: 300 mg CQ + 500 mg IG = 800 mg of compound per day. | Significant reduction in Cholesterol and LDL of FBG levels. | [ |
| -Control group: placebo, | Control group: 800 of placebo per day. | Significant decrease in body weight, body fat percent, and waist size in both groups. | ||
| -Intervention group: compound of CQ and IG, | Duration: 10 weeks | |||
| coronary heart disease (CHD) patients | Group I: placebo capsules; | Significant antioxidant action in the vitamin E group and | [ | |
| Group I: control group, | Group II: vitamin E capsules 400 units per day; | Significant hypo-cholesterolemic effect in the | ||
| Group II: vitamin E group, | Group III received finely pulverized | |||
| Group III: | for 30 days. | |||
| Ginger ( | Diabetic adults | 3 g of each per day | Reduction in FBS and HbA1c. | [ |
| -Control group: placebo, | for 8 weeks. | Improvement in insulin resistance. | ||
| -Intervention group: ginger powder, | ||||
| Black seed ( | Males with MetS | Black seeds (1.5 g/day) | Black seeds reduced lipids and FBG, while turmeric reduced LDL-cholesterol and C-reactive protein (CRP). | [ |
| -Control group: | Turmeric (2.4 g/day) | |||
| Placebo group, | combination (900 mg Black seeds and 1.5 g Turmeric/day) | |||
| -Treatment group: | placebo (2 g) | |||
| -Turmeric group, | for 8 weeks. | |||
| -Black seed group, | ||||
| -Combination group, | ||||
| Cinnamon, cardamom, saffron ( | Type 2 diabetes participants | For 8 weeks, | Significant beneficial effects on cholesterol, but not on measures of glycemic control, oxidative stress, and inflammation. | [ |
| -Control group: | three glasses of black tea and either 3 g/day of cardamom, or cinnamon, or ginger, or 1 g saffron. Control group received three tea glasses without any treatment. | |||
| Placebo, | ||||
| -Treatment groups: | ||||
| Cinnamon, | ||||
| Cardamom, | ||||
| Saffron, | ||||
| Ginger, |
Figure 1Common spices used in food, and their impact on MetS risk factors.